Literature DB >> 8427999

Basic fibroblast growth factor counteracts the suppressive effect of transforming growth factor-beta 1 on human myeloid progenitor cells.

J L Gabrilove1, G Wong, E Bollenbacher, K White, S Kojima, E L Wilson.   

Abstract

We have previously shown that basic fibroblast growth factor (bFGF) is mitogenic for human bone marrow stromal cells and enhances myelopoiesis in human long-term bone marrow culture. In the present study, we examined the mechanism by which bFGF enhances granulopoiesis. We observed that bFGF significantly abrogated the inhibitory effect of transforming growth factor-beta 1 (TGF-beta 1) on granulocyte-macrophage colony-stimulating factor (GM-CSF)-supported progenitor cell growth (P = .009). The partial reversal of TGF-beta 1-mediated suppression was dependent on the dose of bFGF used. In addition, we noted that the inclusion of neutralizing antibody to TGF-beta 1 significantly augmented the clonogenic response to GM-CSF. We have also shown that 10 ng/mL or 100 ng/mL of bFGF resulted in a 30% to 100% increase in GM-CSF-mediated progenitor cell growth (P = .0001). These data suggest that bFGF may enhance myelopoiesis by modulating the inhibitory response to TGF-beta 1.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8427999

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Cytokine production by a megakaryocytic cell line.

Authors:  B Sandrock; K M Hudson; D E Williams; M A Lieberman
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-04       Impact factor: 2.416

2.  Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice.

Authors:  D L Miller; S Ortega; O Bashayan; R Basch; C Basilico
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

Review 3.  Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia.

Authors:  M C Le Bousse-Kerdilès; M C Martyré
Journal:  Springer Semin Immunopathol       Date:  1999

4.  Effects of nerve growth factor (NGF) and other fibroblast-derived growth factors on immature human mast cells (HMC-1).

Authors:  P Welker; J Grabbe; A Grützkau; B M Henz
Journal:  Immunology       Date:  1998-07       Impact factor: 7.397

5.  Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias.

Authors:  K J McGraw; M G Rosenblum; L Cheung; D A Scheinberg
Journal:  Cancer Immunol Immunother       Date:  1994-12       Impact factor: 6.968

6.  Tumor necrosis factor alpha is a potent synergistic factor for the proliferation of primitive human hematopoietic progenitor cells and induces resistance to transforming growth factor beta but not to interferon gamma.

Authors:  H W Snoeck; S Weekx; A Moulijn; F Lardon; M Lenjou; G Nys; P C Van Ranst; D R Van Bockstaele; Z N Berneman
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

Review 7.  Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies.

Authors:  Mohamed R Akl; Poonam Nagpal; Nehad M Ayoub; Betty Tai; Sathyen A Prabhu; Catherine M Capac; Matthew Gliksman; Andre Goy; K Stephen Suh
Journal:  Oncotarget       Date:  2016-07-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.